Company: ATRA
Filing Date: 2025-03-07
Form Type: 10-K
Source: 0000950170-25-035507
Chunk: 6

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-03-07
Form: 10-K
Item: Item 15
Chunk 6
---
 31, 2024
     
    10-Q

    10.2
     
    08/12/2024

    10.34+
     
    Amended and Restated Commercialization Agreement by and between Atara Biotherapeutics, Inc. and Pierre Fabre Medicament dated October 31, 2023
     
    10-K

    10.31
     
    03/28/2024

    10.35*
     
    Atara Biotheraputics, Inc. 2024 Equity Incentive Plan
     
    S-8

    4.4
     
    6/11/2024

    19.1
     
    Insider Trading and Window Period Policy

    X

    21.1
     
    List of Subsidiaries

    X

    23.1
     
    Consent of Independent Registered Public Accounting Firm

    X

    24.1
     
    Power of Attorney (included on signature page)

    31.1
     
    Certification of the Chief Executive Officer pursuant to Rules 13A-14A and 15D-14A of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

    X

    31.2
     
    Certification of the Chief Financial Officer pursuant to Rules 13A-14A and 15D-14A of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

    X

    32.1(1)
     
    Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

    X

    97.1
     
    Incentive Compensation Recoupment Policy

    X

    101.INS
     
    Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

    X

    101.SCH
     
    Inline XBRL Taxonomy Extension Schema Document

    X

    101.CAL
     
    Inline XBRL Tax